Despite the limited number of large clinical trials on the positive therapeutic effect of medical marijuana, the several thousand-year history of using cannabis in medicine and numerous reports allow the conclusion that cannabis preparations have a great therapeutic potential. The report presents the clinical case of a 35-year-old female patient treated with medical marijuana preparations due to persistent headache following neurosurgical resection of a brain tumour. Therapy with medical marijuana was started 3 years after surgery. Headache occurred several times a day and responded poorly to NSAIDs, which resulted in the patient often giving-up pharmacological treatment. The applied treatment with dried cannabis with high THC content taken by vaporization in a finally dose of 0.1 g twice a day showed a significant reduction in pain by 7–9 on the NRS within the 3 months of therapy. This observation suggests a significant analgesic effect of cannabis in the treatment of symptomatic headaches.
Kurzepa J, Wezgraj W, Luchowska-Kocot D. Significant reduction of symptomatic headache by medical marijuana. Case report. J Pre-Cin Clin Rs. 2021; 15(4): 162–164. doi: 10.26444/jpccr/142773
Costa B, Trovato AE, Comelli F, et al. The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. Eur J Pharmacol. 2007; 556: 75–83. 10.1016/j.ejphar.2006.11.006.
Thomas A, Baillie GL, Phillips AM, et al. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol. 2007; 150: 613–623. 10.1038/sj.bjp.0707133.
Ferber SG, Namdar D, Hen-Shoval D, et al. The “Entourage Effect”: Terpenes Coupled with Cannabinoids for the Treatment of Mood Disorders and Anxiety Disorders. Curr Neuropharmacol. 2020; 18(2): 87–96. doi: 10.2174/1570159X17666190903103923.
Cogan PS. The ‘entourage effect’ or ‘hodge-podge hashish’: the questionable rebranding, marketing, and expectations of cannabis polypharmacy. Expert Rev Clin Pharmacol. 2020; 13(8): 835–845. doi: 10.1080/17512433.2020.1721281.
Amin MR, Ali DW. Pharmacology of Medical Cannabis. Adv Exp Med Biol. 2019; 1162: 151–165. doi: 10.1007/978-3-030-21737-2_8.
Vučković S, Srebro D, Vujović KS, et al. Cannabinoids and Pain: New Insights From Old Molecules. Front Pharmacol. 2018; 13(9):1259. doi: 10.3389/fphar.2018.01259.
Lochte BC, Beletsky A, Samuel NK, Grant I. The Use of Cannabis for Headache Disorders. Cannabis Cannabinoid Res. 2017; 2(1): 61–71. doi: 10.1089/can.2016.0033.
Mechtler L, Bargnes V, Hart P, et al. Medical Cannabis for Chronic Migraine: A Retrospective Review (P3.10–015). Neurology. 2019; 92: P3.10–015.
Citti C, Pacchetti B, Vandelli MA, et al. Analysis of cannabinoids in commercial hemp seed oil and decarboxylation kinetics studies of cannabidiolic acid (CBDA). J Pharm Biomed Anal. 2018; 5; 149: 532–540. doi: 10.1016/j.jpba.2017.11.044. Epub 2017 Nov 20.
Romero-Sandoval EA, Kolano AL, Alvarado-Vázquez PA. Cannabis and Cannabinoids for Chronic Pain. Curr Rheumatol Rep. 2017; 19(11): 67. doi: 10.1007/s11926-017-0693-1.
Woodhams SG, Chapman V, Finn DP, et al. The cannabinoid system and pain. Neuropharmacology. 2017; 15(124): 105–120. doi: 10.1016/j.neuropharm.2017.06.015.
Pergolizzi JV Jr, Lequang JA, Taylor R Jr, et al. The role of cannabinoids in pain control: the good, the bad, and the ugly. Minerva Anestesiol. 2018; 84(8): 955–969. doi: 23736/S0375-9393.18.12287-5. Epub 2018 Jan 16.
Andreae MH, Carter GM, Shaparin N, et al. Inhaled Cannabis for Chronic Neuropathic Pain: A Meta-analysis of Individual Patient Data. J Pain. 2015; 16(12): 1221–1232. doi: 10.1016/j.jpain.2015.07.009.
Abrams DI. The therapeutic effects of Cannabis and cannabinoids: An update from the National Academies of Sciences, Engineering and Medicine report. Eur J Intern Med. 2018; 49: 7–11. doi: 10.1016/j.ejim.2018.01.003. Epub 2018 Jan 9.
Likar R, Nahler G. The use of cannabis in supportive care and treatment of brain tumor. Neurooncol Pract. 2017; 4(3): 151–160. doi: 10.1093/nop/npw027. Epub 2017 Jan 18.
Ferber SG, Namdar D, Hen-Shoval D, et al. The “Entourage Effect”: Terpenes Coupled with Cannabinoids for the Treatment of Mood Disorders and Anxiety Disorders. Curr Neuropharmacol. 2020; 18(2): 87–96. doi:10.2174/1570159X17666190903103923.
Rosenberg EC, Tsien RW, Whalley BJ, Devinsky O. Cannabinoids and Epilepsy. Neurotherapeutics. 2015; 12(4): 747–68. doi: 10.1007/s13311-015-0375-5.
Hart S, Fischer OM, Ullrich A. Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res. 2004; 64(6): 1943–50. doi: 10.1158/0008-5472.can-03-3720.
Galanti G, Fisher T, Kventsel I, et al. Delta 9-tetrahydrocannabinol inhibits cell cycle progression by downregulation of E2F1 in human glioblastoma multiforme cells. Acta Oncol. 2008; 47(6): 1062–70. doi: 10.1080/02841860701678787.
Journals System - logo
Scroll to top